Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a non-steroidal anti-inflammatory (NSAID), selective inhibitor of cyclooxygenase-2 (COX-2) that is used in the treatment of rheumatoid arthritis and other rheumatic diseases. Oral administration once daily.
At latest update, relevant information on excretion into breast milk was not found.
Due to a high serum-protein-binding capacity, excretion into breast milk seems to be unlikely.
Expert authors consider the use of meloxicam to be probably safe during breastfeeding (Briggs 2015). A similar agent, piroxicam, is classified as compatible with breastfeeding by the American Academy of Pediatrics
Until more information on this drug is available, another know therapeutic alternative should be preferred, especially in cases of breastfeeding an infant younger than one month or prematures.